000963 Huadong Medicine Co.,Ltd.
Closed 04-10 15:00:00
36.05
+0.10
+0.28%
High36.50Low35.81Vol10.82M
Open35.87D1 Closing35.95Amplitude1.92%
Mkt Cap63.23BTradable Cap63.20BTotal Shares1.75B
T/O391.00MT/O Rate0.62%Tradable Shares1.75B
P/B2.61ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue
Reuters  ·  04-10 21:07
CARsgen publishes 2025 annual report, posts RMB 125.7 million revenue
Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era
Stock News  ·  03-27
Global First Recombinant Botulinum Toxin Type A Approved, Huadong Medicine Ushers in New Era
China Stocks Jump on Positive Industrial Profit Growth
MT Newswires Live  ·  03-27
China Stocks Jump on Positive Industrial Profit Growth
Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial
MT Newswires Live  ·  03-27
Huadong Medicine's Unit Gets Nod for HDM2024 for Injection's Clinical Trial
Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial
Stock News  ·  03-26
Huadong Medicine Subsidiary Gets Nod for HDM2024 Injection Clinical Trial
Huadong Medicine Unit Gets US FDA's Nod to Trial Advanced Tumor Drug
MT Newswires Live  ·  03-12
Huadong Medicine Unit Gets US FDA's Nod to Trial Advanced Tumor Drug
Huadong Medicine's Investigational Drug HDM2024 Receives FDA Clearance for US Clinical Trial
Stock News  ·  03-11
Huadong Medicine's Investigational Drug HDM2024 Receives FDA Clearance for US Clinical Trial
Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications
Deep News  ·  03-06
Leading Pharmaceutical Firms Race to Launch Oral Weight-Loss Medications
CARsgen posts FY2025 net loss of CNY103 million, down 87%
Reuters  ·  03-06
CARsgen posts FY2025 net loss of CNY103 million, down 87%
Press Release: CARsgen Therapeutics Announces 2025 Annual Results
Dow Jones  ·  03-06
Press Release: CARsgen Therapeutics Announces 2025 Annual Results
Huadong Medicine Co.,Ltd. Announces Controlling Shareholder Releases 49 Million Shares from Pledge
Deep News  ·  03-06
Huadong Medicine Co.,Ltd. Announces Controlling Shareholder Releases 49 Million Shares from Pledge
Huadong Medicine Obtains Greenlight for Cancer Drug Trial
MT Newswires Live  ·  03-03
Huadong Medicine Obtains Greenlight for Cancer Drug Trial
Huadong Medicine's Subsidiary Gains Approval for Clinical Trial of DR30206 Injection
Stock News  ·  03-02
Huadong Medicine's Subsidiary Gains Approval for Clinical Trial of DR30206 Injection
Huadong Medicine Appeals to Supreme Court After Losing Initial Patent Lawsuit Against Jolly Pharmaceutical
Deep News  ·  02-27
Huadong Medicine Appeals to Supreme Court After Losing Initial Patent Lawsuit Against Jolly Pharmaceutical
Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial
MT Newswires Live  ·  02-05
Huadong Medicine's Unit Gets Nod for Hypertriglyceridemia Drug Clinical Trial
Huadong Medicine Subsidiary's DR10624 Injection Receives Clinical Trial Approval
Stock News  ·  02-04
Huadong Medicine Subsidiary's DR10624 Injection Receives Clinical Trial Approval
China's Drug Regulator Accepts Marketing Authorization Application of Huadong Medicine's Unit for Roflumilast Cream
MT Newswires Live  ·  02-04
China's Drug Regulator Accepts Marketing Authorization Application of Huadong Medicine's Unit for Roflumilast Cream
Huadong Medicine (000963.SZ): Roflumilast Cream Marketing Authorization Application Accepted
Stock News  ·  02-03
Huadong Medicine (000963.SZ): Roflumilast Cream Marketing Authorization Application Accepted
Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market
Deep News  ·  01-27
Huadong Medicine: HDM1002, as a differentiated oral GLP-1 targeted drug, is positioned to meet unmet and differentiated clinical needs in the global market
Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial
MT Newswires Live  ·  01-15
Huadong Medicine Gets U.S. Regulatory Nod for Liver Disease Drug Trial

Introduction

Company Name.
华东医药股份有限公司
Industry:
零售业
Listing Date:
2000-01-27
Main Business:
　　华东医药股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是商业、制造业、医美业务。公司凭借优秀的ESG治理能力，WINDESG评级从A级提升至AA级，此外，公司目前MSCIESG评级A级，深交所国证ESG评级AA级，并且获得2024《新财富》杂志“ESG最佳实践”,E药经理人“2025生物医药可持续价值领航奖”等荣誉。
Issue price:
5.76